盘龙药业(002864.SZ)：获得药物临床试验批准通知书

Core Viewpoint - The approval of clinical trials for the drug Fluorobufen patch by the National Medical Products Administration represents a significant advancement for the company in the pain management sector, particularly for musculoskeletal conditions [1] Group 1: Product Development - The Fluorobufen patch, developed by Daiichi Sankyo Co., Ltd., was first approved for sale in Japan on July 23, 1998 [1] - The patch is indicated for pain relief and inflammation for conditions such as osteoarthritis, periarthritis of the shoulder, tendinitis, and muscle pain [1] - The product is classified as a Class 3 chemical drug and has not yet been launched in the domestic market [1] Group 2: Product Features - The patch features a controlled-release membrane design, which allows for a large drug load, low irritation, and reduced risk of skin allergies [1] - It is particularly suitable for chronic pain conditions and scenarios requiring high adhesion and flexibility in patches [1] Group 3: Strategic Implications - Successful development of this project will enhance the company's product portfolio in the musculoskeletal field [1] - The new product will complement the company's core offerings in treatment areas, distribution channels, and target customer groups, thereby strengthening brand and market barriers [1] - The integration of "oral + topical" orthopedic product solutions will be further improved [1]